Shares of Symbotic plunged 29% during December after the company and a major shareholder sold a combined 10 million shares in early December. This transaction followed a stellar fourth-quarter report in late November that had driven the stock up by more than 150% over the prior twelve months. Investors reacted strongly to the dilution effect of the equity raise, with the offering priced at a discount of roughly 25% to the prevailing market level in order to attract sufficient demand for the large block.

Of the 10 million shares sold, 3.5 million came from SoftBank, which retained the proceeds, while the remaining 6.5 million were issued by Symbotic to bolster its balance sheet. Although SoftBank’s sale amounted to less than 10% of its nearly 40 million‐share stake, the timing raised eyebrows. SoftBank has been liquidating positions in high‐flyers to fund its multibillion‐dollar commitments elsewhere, but its continued holding of over 90% of its Symbotic stake underscores confidence in the warehouse robotics specialist’s long‐term prospects.

Following the raise, Symbotic’s cash and equivalents stand near the $1.25 billion reported at the end of the September quarter, supported by positive free cash flow last year. The capital infusion of approximately $358 million suggests management sees the current valuation—around 18.6 times last year’s revenue—as an opportunity to fund expansion rather than a necessity for liquidity. Management forecasts revenue growth of 27% at the midpoint for the upcoming quarter, a mild acceleration over the 26% growth achieved in the last fiscal year, while diversification into the healthcare segment offers a potential avenue to reduce concentration risk away from the company’s largest e-commerce customer.